BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: García-Samaniego J, Romero M, Granados R, Alemán R, Jorge Juan M, Suárez D, Pérez R, Castellano G, González-Portela C. Factors associated with early virological response to peginterferon-α-2a/ribavirin in chronic hepatitis C. World J Gastroenterol 2013; 19(12): 1943-1952 [PMID: 23569340 DOI: 10.3748/wjg.v19.i12.1943]
URL: https://www.wjgnet.com/1007-9327/full/v19/i12/1943.htm
Number Citing Articles
1
Wan‐Long Chuang, Rong‐Nan Chien, Cheng‐Yuan Peng, Ting‐Tsung Chang, Gin‐Ho Lo, I‐Shyan Sheen, Horng‐Yuan Wang, Jyh‐Jou Chen, Jenny C. Yang, Steven J. Knox, Bing Gao, Kimberly L. Garrison, Hongmei Mo, Phillip S. Pang, Yu‐Chun Hsu, Tsung‐Hui Hu, Chi‐Jen Chu, Jia‐Horng Kao. Ledipasvir/sofosbuvir fixed‐dose combination tablet in Taiwanese patients with chronic genotype 1 hepatitis C virusJournal of Gastroenterology and Hepatology 2016; 31(7): 1323 doi: 10.1111/jgh.13305
2
Elena Gentilcore. Long-term outcomes after hepatitis C virus eradication: a message for cliniciansMinerva Medica 2020; 110(6) doi: 10.23736/S0026-4806.19.06211-6
3
S. H. Ahn, Y. S. Lim, K. S. Lee, S. W. Paik, Y. J. Lee, S. H. Jeong, J. H. Kim, S. K. Yoon, H. J. Yim, W. Y. Tak, S. Y. Han, J. C. Yang, H. Mo, A. Mathias, L. Han, S. J. Knox, D. M. Brainard, Y. J. Kim, K. S. Byun, Y. S. Kim, J. Heo, K. H. Han. A phase 3b study of sofosbuvir plus ribavirin in treatment‐naive and treatment‐experienced Korean patients chronically infected with genotype 2 hepatitis C virusJournal of Viral Hepatitis 2016; 23(5): 358 doi: 10.1111/jvh.12499
4
Jia‐Horng Kao, Rong‐Nan Chien, Ting‐Tsung Chang, Cheng‐Yuan Peng, Tsung‐Hui Hu, Gin‐Ho Lo, Horng‐Yuan Wang, Jyh‐Jou Chen, Jenny C. Yang, Steven J. Knox, Lingling Han, Hongmei Mo, Anita Mathias, Diana M. Brainard, I‐Shyan Sheen, Yu‐Chun Hsu, Chi‐Jen Chu, Wan‐Long Chuang. A phase 3b study of sofosbuvir plus ribavirin in Taiwanese patients with chronic genotype 2 hepatitis C virus infectionLiver International 2016; 36(8): 1101 doi: 10.1111/liv.13082
5
Chiara Rosso, Maria Lorena Abate, Alessia Ciancio, Silvia Strona, Gian Paolo Caviglia, Antonella Olivero, Giovanni Antonio Touscoz, Mario Rizzetto, Rinaldo Pellicano, Antonina Smedile. <italic>IL28B</italic> polymorphism genotyping as predictor of rapid virologic response during interferon plus ribavirin treatment in hepatitis C virus genotype 1 patientsWorld Journal of Gastroenterology 2014; 20(36): 13146-13152 doi: 10.3748/wjg.v20.i36.13146
6
Young-Suk Lim, Sang Hoon Ahn, Kwan Sik Lee, Seung Woon Paik, Youn-Jae Lee, Sook-Hyang Jeong, Ju-Hyun Kim, Seung Kew Yoon, Hyung Joon Yim, Won Young Tak, Sang-Young Han, Jenny C. Yang, Hongmei Mo, Kimberly L. Garrison, Bing Gao, Steven J. Knox, Phillip S. Pang, Yoon Jun Kim, Kwan-Soo Byun, Young Seok Kim, Jeong Heo, Kwang-Hyub Han. A phase IIIb study of ledipasvir/sofosbuvir fixed-dose combination tablet in treatment-naïve and treatment-experienced Korean patients chronically infected with genotype 1 hepatitis C virusHepatology International 2016; 10(6): 947 doi: 10.1007/s12072-016-9726-5
7
Young Min Kim, Suk Bae Kim, Il Han Song, Sae Hwan Lee, Hong Soo Kim, Tae Hee Lee, Young Woo Kang, Seok Hyun Kim, Byung Seok Lee, Hee Bok Chae, Myeong Jun Song, Ji Woong Jang, Soon Young Ko, Jae Dong Lee. Efficacy and safety of sofosbuvir plus ribavirin for Korean patients with hepatitis C virus genotype 2 infection: A retrospective multi-institutional studyClinical and Molecular Hepatology 2018; 24(3): 311 doi: 10.3350/cmh.2017.0070